DO -- Pharmaceutical analysts believe stockholders of Frazer, Pa.-based drugmaker Cephalon Inc. will be open to a $73-per-share takeover bid from Ontario-based Valeant Pharmaceuticals. Valeant made its bid to acquire Cephalon public earlier this week after Cephalon rebuffed Valeant's private attempts to negotiate with the company.
